The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer

Clinical and Experimental Pharmacology & Physiology
Muyang DingYane Gao

Abstract

Enhancer of zeste 2 (EZH2), a polycomb histone methyltransferase, is overexpressed in various cancers, including cervical cancer. Gene expression analysis revealed that increased expression of EZH2 is associated with cervical cancer progression, particularly the progression to invasive squamous cell carcinoma. Enhancer of zeste 2 is known to trimethylate lysine 27 on histone H3, leading to gene silencing that contributes to the progression of tumours into a more aggressive form of cancer. However, the specific molecular mechanisms by which EZH2 contributes to the development of cervical cancer remain largely unknown. Recently, an EZH2 inhibitor was reported to selectively inhibit trimethylated lysine 27 on histone H3 and to reactivate silenced genes in cancer cells. In this study, we found that GSK343 (a specific inhibitor of EZH2 methyltransferase) induces phenotypic reprogramming of cancer cells from mesenchymal to epithelial cells, reducing proliferation and cell motility and blocking the invasion of cervical cancer cell lines both in vitro and in vivo. Treatment with the EZH2 inhibitor led to increased levels of the epithelial marker E-cadherin and decreased levels of mesenchymal markers such as N-cadherin and vimentin. The...Continue Reading

References

Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingeborg M BachmannLars A Akslen
Aug 30, 2008·Mutation Research·Jeffrey A Simon, Carol A Lange
Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Jan 21, 2011·Nature·Raphaël Margueron, Danny Reinberg
May 27, 2011·Breast Cancer Research and Treatment·Sharon Hensley AlfordCelina G Kleer
Jun 20, 2012·Cancer Metastasis Reviews·Francesco CreaRomano Danesi
Oct 22, 2013·Genes & Development·Jeff H Tsai, Jing Yang
Dec 13, 2012·ACS Medicinal Chemistry Letters·Sharad K VermaWilliam H Miller
Aug 15, 2014·Oncotarget·Swathi ChinaranagariJaideep Chaudhary
Aug 19, 2014·Nature Reviews. Drug Discovery·Katrina J Falkenberg, Ricky W Johnstone

❮ Previous
Next ❯

Citations

Feb 20, 2016·Clinical and Experimental Pharmacology & Physiology·Jun-Ping Liu
Oct 30, 2016·Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'oto-rhino-laryngologie Et De Chirurgie Cervico-faciale·Sherif IdrisVincent L Biron
Aug 25, 2016·Oncotarget·Neil Ari WijetungaJohn M Greally
Aug 16, 2017·Oncoimmunology·Marcello RubinoCecilia Garlanda
Jul 6, 2019·Journal of Cellular and Molecular Medicine·Hongjuan SongGuilin Li
Mar 11, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Talha AnwarCelina G Kleer
Feb 7, 2018·Biology of Reproduction·Mariano Colón-CaraballoIdhaliz Flores
Nov 22, 2015·Molecular Cancer Therapeutics·Henar HernandoCarlo Stresemann
Mar 11, 2021·PloS One·Laura V BownesElizabeth A Beierle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.